Locations:
SearchCleveland Clinic oncologist reviews new agents
Several new agents are showing promising results in treating non Hodgkin lymphomas (NHL). They include ibrutinib, venetoclax, idelalisib, chimeric antigen receptor (CAR)–modified T-cell therapy and obinutuzumab.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In this interview with OncLive.com, medical oncologist Mitchell Smith, MD, of Cleveland Clinic Cancer Center’s Department of Hematology and Medical Oncology discusses these recent NHL advances, some of which have “game-changing” potential.
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust